Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.
Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.
复制标题
DOI：
10.1186/1471-2407-10-462
复制
发表时间：
2010-08-29
期刊：
影响因子：
3.8
通讯作者：
Athanasou N
中科院分区：
文献类型：
--
作者：
Balke M;Campanacci L;Gebert C;Picci P;Gibbons M;Taylor R;Hogendoorn P;Kroep J;Wass J;Athanasou N
骨巨细胞瘤（GCTB）是一种含有大量破骨细胞样巨细胞的膨胀性溶骨性肿瘤。GCTB经常复发，并可在肺部产生转移性病变。双膦酸盐是主要作用于破骨细胞的抗骨吸收药物。在这项研究中，我们研究了临床和放射学结果与氨基二膦酸盐治疗25例侵略性原发性，复发性和转移性GCTB来自四个欧洲中心。我们还分析了唑来膦酸对从GCTB分离的破骨细胞的体外抑制作用。治疗方案不同，采用了几种不同的氨基二膦酸盐，但在大多数这些病例中，疾病的稳定是难以治疗的常规治疗。大多数不能手术的骶骨/骨盆肿瘤大小没有增加，在骨和软组织中反复复发的GCTB中没有进一步复发。治疗后肺转移瘤的大小或数量没有增加。唑来膦酸在体外可明显抑制GCTB源性破骨细胞的骨吸收。我们的研究结果表明，双膦酸盐可能是有用的，在控制疾病进展GCTB和这些药物直接抑制GCTB衍生的破骨细胞吸收。这些研究强调需要建立标准化的方案来评估双膦酸盐治疗GCTB的疗效。
Giant cell tumour of bone (GCTB) is an expansile osteolytic tumour which contains numerous osteoclast-like giant cells. GCTB frequently recurs and can produce metastatic lesions in the lungs. Bisphosphonates are anti-resorptive drugs which act mainly on osteoclasts. In this study, we have examined clinical and radiological outcomes of treatment with aminobisphosphonates on 25 cases of aggressive primary, recurrent and metastatic GCTB derived from four European centres. We also analysed in vitro the inhibitory effect of zoledronic acid on osteoclasts isolated from GCTBs. Treatment protocols differed with several different aminobisphosphonates being employed, but stabilisation of disease was achieved in most of these cases which were refractory to conventional treatment. Most inoperable sacral/pelvic tumours did not increase in size and no further recurrence was seen in GCTBs that had repeatedly recurred in bone and soft tissues. Lung metastases did not increase in size or number following treatment. Zoledronic acid markedly inhibited lacunar resorption by GCTB-derived osteoclasts in vitro. Our findings suggest that bisphosphonates may be useful in controlling disease progression in GCTB and that these agents directly inhibit GCTB - derived osteoclast resorption. These studies highlight the need for the establishment of standardised protocols to assess the efficacy of bisphosphonate treatment of GCTB.
登录
查看更多内容
DOI：
10.2106/00004623-198769010-00018
发表时间：
1987-01-01
影响因子：
5.3
作者：
CAMPANACCI, M;BALDINI, N;SUDANESE, A
通讯作者：
SUDANESE, A
影响因子：
4.2
作者：
Cheng, YY;Huang, L;Kumta, SM
通讯作者：
Kumta, SM
影响因子：
51.1
作者：
Thomas, David;Henshaw, Robert;Jun, Susie
通讯作者：
Jun, Susie
影响因子：
6.2
作者：
Chapurlat, RD;Delmas, PD;Meunier, PJ
通讯作者：
Meunier, PJ
影响因子：
4.1
作者：
Nishikawa, M;Akatsu, T;Nagata, N
通讯作者：
Nagata, N